Vaxart Inc
F:NB11
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vaxart Inc
F:NB11
|
US |
|
P
|
Phillips Edison & Co Inc
F:9R4
|
US |
|
Nippon Sanso Holdings Corp
F:NPX
|
JP |
|
V
|
Vimian Group AB
STO:VIMIAN
|
SE |
|
E
|
Extreme Networks Inc
XMUN:EXM
|
US |
|
Master Drilling Group Ltd
F:I49
|
ZA |
|
Sibanye Stillwater Ltd
F:47VS
|
ZA |
|
Gladstone Commercial Corp
NASDAQ:GOOD
|
US |
|
DNB Bank ASA
F:D1N
|
NO |
|
XBiotech Inc
NASDAQ:XBIT
|
US |
|
P
|
Proto Labs Inc
F:PRZ
|
US |
Wall St Price Targets
NB11 Price Targets Summary
Vaxart Inc
According to Wall Street analysts, the average 1-year price target for NB11 is 2.42 EUR with a low forecast of 2.4 EUR and a high forecast of 2.49 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NB11's stock price target?
Price Target
2.42
EUR
According to Wall Street analysts, the average 1-year price target for NB11 is 2.42 EUR with a low forecast of 2.4 EUR and a high forecast of 2.49 EUR.
What is the Revenue forecast for Vaxart Inc?
Projected CAGR
-9%
Over the last 7 years, the compound annual growth rate for Revenue has been 78%. The projected CAGR for the next 7 years is -9%.
What is the Operating Income forecast for Vaxart Inc?
Projected CAGR
-5%
The compound annual growth rate for Operating Income over the next 7 years is -5%.
